Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 – Part I

Bibliography

• Huang EJ, Reichardt LF. NEUROTROPHINS: roles in neuronal development and function. Annu Rev Neurosci. 2001;24(1):677–736.
   PubMed Web of Science ®Google Scholar
• Klein R, Jing S, Nanduri V, et al. The trk proto-oncogene encodes a receptor for nerve growth factor. Cell. 1991;65(1):189–197.
   PubMed Web of Science ®Google Scholar
• Kaplan DR, Martin-Zanca D, Parada LF. Tyrosine phosphorylation and tyrosine kinase activity of the trk proto-oncogene product induced by NGF. Nature. 1991;350(6314):158–160.
   PubMed Web of Science ®Google Scholar
• Klein R, Nanduri V, Jing S, et al. The trkB tyrosine protein kinase is a receptor for brain-derived neurotrophic factor and neurotrophin-3. Cell. 1991;66(2):395–403.
   PubMed Web of Science ®Google Scholar
• Lamballe F, Klein R, Barbacid M. trkC, a new member of the trk family of tyrosine protein kinases, is a receptor for neurotrophin-3. Cell. 1991;66(5):967–979.
   PubMed Web of Science ®Google Scholar
• Siniscalco D, Giordano C, Rossi F, et al. Role of neurotrophins in neuropathic pain. Curr Neuropharmacol. 2011;9(4):523–529.
   PubMed Web of Science ®Google Scholar
• Gupta VK, You Y, Gupta VB, et al. TrkB receptor signalling: implications in neurodegenerative, psychiatric and proliferative disorders. Int J Mol Sci. 2013;14(5):10122–10142.
   PubMed Web of Science ®Google Scholar
• Brodeur GM, Minturn JE, Ho R, et al. Trk receptor expression and inhibition in neuroblastomas. Clin Cancer Res. 2009;15(10):3244–3250.
   PubMed Web of Science ®Google Scholar
• Sclabas GM, Fujioka S, Schmidt C, et al. Overexpression of tropomysin-related kinase B in metastatic human pancreatic cancer cells. Clin Cancer Res. 2005;11(2):440–449.
   PubMed Web of Science ®Google Scholar
• Yu Y, Zhang S, Wang X, et al. Overexpression of TrkB promotes the progression of colon cancer. APMIS. 2010;118(3):188–195.
   PubMed Web of Science ®Google Scholar
• Vaishnavi A, Le A, Doebele RC. TRKing down an old oncogene in a new era of targeted therapy. Cancer Discov. 2015;5(1):25–34.
   PubMed Web of Science ®Google Scholar
• Bailey JJ, Schirrmacher R, Farrell K, et al. Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 – Part II. Expert Opin Ther Pat. 2017. doi:10.1080/13543776.2017.1297797..
   Google Scholar
• Huse M, Kuriyan J. The conformational plasticity of protein kinases. Cell. 2002;109(3):275–282.
   PubMed Web of Science ®Google Scholar
• Wang T, Lamb ML, Block MH, et al. Discovery of disubstituted Imidazo[4,5-b]pyridines and purines as potent TrkA inhibitors. ACS Med Chem Lett. 2012;3(9):705–709.
   PubMed Web of Science ®Google Scholar
• Bertrand T, Kothe M, Liu J, et al. The crystal structures of TrkA and TrkB suggest key regions for achieving selective inhibition. J Mol Biol. 2012;423(3):439–453.
   PubMed Web of Science ®Google Scholar
• Choi H-S, Rucker PV, Wang Z, et al. (R)-2-phenylpyrrolidine substituted imidazopyridazines: A new class of potent and selective pan-TRK inhibitors. ACS Med Chem Lett. 2015;6(5):562–567.
   PubMed Web of Science ®Google Scholar
• Albaugh P, Fan Y, Mi Y, et al. Discovery of GNF-5837, a selective TRK inhibitor with efficacy in rodent cancer tumor models. ACS Med Chem Lett. 2012;3(2):140–145.
   PubMed Web of Science ®Google Scholar
• Stachel SJ, Sanders JM, Henze DA, et al. Maximizing diversity from a kinase screen: identification of novel and selective pan-Trk inhibitors for chronic pain. J Med Chem. 2014;57(13):5800–5816.
   PubMed Web of Science ®Google Scholar
• Zuccotto F, Ardini E, Casale E, et al. Through the “Gatekeeper Door”: exploiting the active kinase conformation. J Med Chem. 2010;53(7):2681–2694.
   PubMed Web of Science ®Google Scholar
• Hari Sanjay B, Merritt Ethan A, Maly Dustin J. Sequence determinants of a specific inactive protein kinase conformation. Chem Biol. 2013;20(6):806–815.
   PubMedGoogle Scholar
• Garuti L, Roberti M, Bottegoni G. Non-ATP competitive protein kinase inhibitors. Curr Med Chem. 2010;17(25):2804–2821.
   PubMed Web of Science ®Google Scholar
• Wu P, Clausen MH, Nielsen TE. Allosteric small-molecule kinase inhibitors. Pharmacol Ther. 2015;156:59–68.
   PubMed Web of Science ®Google Scholar
• Jia Y, Yun C-H, Park E, et al. Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors. Nature. 2016;534(7605):129–132.
   PubMed Web of Science ®Google Scholar
• Su H-P, Rickert K, Burlein C, et al. Structural characterization of nonactive site, TrkA-selective kinase inhibitors. PNAS. 2017;14:E297–E306.
   Web of Science ®Google Scholar
• Brandhuber BJ, Jiang Y, Kolakowski GR, et al. Pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors. WO2014078417 A1. 2014
   Google Scholar
• Andrews SW, Blake JF, Brandhuber BJ, et al. N-(monocyclic aryl),N’-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors. WO2014078325 A1. 2014
   Google Scholar
• Pargellis C, Tong L, Churchill L, et al. Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site. Nat Struct Mol Biol. 2002;9(4):268–272.
   Web of Science ®Google Scholar
• McElroy WT, Tan Z, Ho G, et al. Potent and selective amidopyrazole inhibitors of IRAK4 that are efficacious in a rodent model of inflammation. ACS Med Chem Lett. 2015;6(6):677–682.
   PubMed Web of Science ®Google Scholar
• Hanisak J, Seganish WM, McElroy WT, et al. Efforts towards the optimization of a bi-aryl class of potent IRAK4 inhibitors. Bioorg Med Chem Lett. 2016;26(17):4250–4255.
   PubMed Web of Science ®Google Scholar
• Scanio M, Bunnelle W, Koenig JR, et al. 6-phenyl- or 6-(pyridin-3-yl)indazole derivatives and methods of use. WO 2015112445 A1. 2015
   Google Scholar
• Tao C, Wang Q, Koroniak L, et al. Ureidophenyl substituted triazine derivatives and their therapeutical applications. WO2010144522 A1. 2010
   Google Scholar
• Bode CM, Cheng AC, Choquette D, et al. Benzimidazole and azabenzimidazole compounds that inhibit anaplastic lymphoma kinase. WO2012018668 A1. 2012
   Google Scholar
• Lewis RT, Bode CM, Choquette DM, et al. The discovery and optimization of a novel class of potent, selective, and orally bioavailable Anaplastic Lymphoma Kinase (ALK) inhibitors with potential utility for the treatment of cancer. J Med Chem. 2012;55(14):6523–6540.
   PubMed Web of Science ®Google Scholar
• Wilcoxen KM Modulating certain tyrosine kinases. WO2013074518 A1. 2013
   Google Scholar
• Weiss GJ, Sachdev JC, Infante JR, et al. Phase (Ph) 1/2 study of TSR-011, a potent inhibitor of ALK and TRK, including crizotinib-resistant ALK mutations. J Clin Oncol. 2014;32:suppl abstr e19005.
   Web of Science ®Google Scholar
• Andrews SW, Haas J, Jiang Y, et al. Substituted imidazo[1,2b]pyridazine compounds as trk kinase inhibitors. WO2010033941 A1. 2010
   Google Scholar
• Ferrand S, Glickman F, Leblanc C, et al. Heterocyclic compounds as antiinflammatory agents. WO2008052734 A1. 2008
   Google Scholar
• Albaugh PA, Choi HS, Chopiuk G, et al. Compounds and compositions as kinase inhibitors. WO2009140128 A2. 2009
   Google Scholar
• Haas J, Andrews SW, Jiang Y, et al. Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors. WO2010048314 A1. 2010
   Google Scholar
• Allen S, Andrews SS, Condroski KR, et al. Substituted Pyrazaolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors. WO2011006074 A1. 2011
   Google Scholar
• Blaney J, Gibbons PA, Hanan E, et al. Pyrazolopyrimidine jak inhibitor compounds and methods. WO2010051549 A1. 2010
   Google Scholar
• Andrews SW, Condroski KR, Haas J, et al. Macrocyclic compounds as inhibitors of trk kinase. WO2011146336 A1. 2011
   Google Scholar
• Hu X-G, Thomas DS, Griffith R, et al. Stereoselective fluorination alters the geometry of a cyclic peptide: exploration of backbone-fluorinated analogues of unguisin A. Angew Chem Int Ed. 2014;53(24):6176–6179.
   PubMed Web of Science ®Google Scholar
• Johnson TW, Richardson PF, Bailey S, et al. Discovery of (10R)-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations. J Med Chem. 2014;57(11):4720–4744.
   PubMed Web of Science ®Google Scholar
• Rankovic Z. CNS Drug design: Balancing physicochemical properties for optimal brain exposure. J Med Chem. 2015;58(6):2584–2608.
   PubMed Web of Science ®Google Scholar
• Allen S, Andrews SW, Blake JF, et al. Pyrrolidinyl urea and pyrrolidinyl thiourea compounds as trka kinase inhibitors. WO2012158413 A3. 2013
   Google Scholar
• Cirillo PF, Gilmore TA, Hickey ER, et al. Aromatic heterocyclic compounds as antiinflammatory agents. WO2000043384 A1. 2000
   Google Scholar
• Allen S, Andrews SW, Blake JF, et al. Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors. WO2014078372 A1. 2014
   Google Scholar
• Allen S, Andrews SW, Blake JF, et al. N-pyrrolidinyl compounds of urea, thio-urea, guanidine and dicyandiamide as inhibitors of the kinase TrkA. WO2014078378 A1. 2014
   Google Scholar
• Allen S, Brandhuber BJ, Kercher T, et al. N-pyrrolidinyl, N’-pyrazolyl- urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors. WO2014078323 A1. 2014
   Google Scholar
• Allen S, Andrews SW, Blake JF, et al. Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain. WO2014078454 A1. 2014
   Google Scholar
• Allen S, Blake JF, Brandhuber BJ, et al. N-bicyclic aryl,N’-pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors. WO2014078328 A1. 2014
   Google Scholar
• Allen S, Brandhuber BJ, Condroski KR, et al. Bicyclic heteroaryl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors. WO2014078408 A1. 2014
   Google Scholar
• Brandhuber BJ, Jiang Y, Kolakowski GR, et al. Thiazolyl and oxazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors. WO2014078322 A1. 2014
   Google Scholar
• Blake JF, Brandhuber BJ, Haas J, et al. N-(arylalkyl)-N’-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors. WO2014078331 A1. 2014
   Google Scholar
• Andrews SW. Allosteric small molecule inhibitors of the NGF/TrkA pathway, A new approach to treating inflammatory pain. [Internet]. Boulder (CO): Array BioPharma Inc; 2012 [cited Aug 17 2016]. Available from: http://arraybiopharma.com/files/6313/9810/8021/PubAttachment587.pdf
   Google Scholar
• Nwosu LN, Mapp PI, Chapman V, et al. Blocking the tropomyosin receptor kinase A (TrkA) receptor inhibits pain behaviour in two rat models of osteoarthritis. Ann Rheum Dis. 2015;17(6):1246–1254.
   Google Scholar
• Ashraf S, Bouhana KS, Pheneger J, et al. Selective inhibition of tropomyosin-receptor-kinase A (TrkA) reduces pain and joint damage in two rat models of inflammatory arthritis. Arthritis Res Ther. 2016;18(1):1–11.
   PubMed Web of Science ®Google Scholar
• Allen S, Andrews SW, Baer B, et al. 1-((3S,4R)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(2-methylpyrimidin-5-yl)-1-phenyl-1h-pyrazol-5-yl)urea as a trka kinase inhibitor. WO2015175788 A1. 2015
   Google Scholar
• John V, Zhang Q, Bredesen DE Trka as a target for inhibiting app cleavage and/or progression of alzheimer’s disease. WO2013026021 A2. 2013
   Google Scholar
• Williams BJ, Eriksdotter-Jonhagen M, Granholm A-C. Nerve growth factor in treatment and pathogenesis of Alzheimer’s disease. Prog Neurobiol. 2006;80(3):114–128.
   PubMed Web of Science ®Google Scholar
• Mufson EJ, Counts SE, Perez SE, et al. Cholinergic system during the progression of Alzheimer’s disease: therapeutic implications. Expert Rev Neurother. 2008;8(11):1703–1718.
   PubMedGoogle Scholar
• Kim M, Lee C, Lee G, et al. Fused ring heteroaryl compounds and their use as trk inhibitors. WO2016097869 A1. 2016
   Google Scholar
• Traversa S, Roblin D, Forster E, et al. Polymer conjugates of indolocarbazole compounds in the treatment of pruritus. WO2014177510 A2. 2014
   Google Scholar
• Roblin D, Yosipovitch G, Boyce B, et al. Topical TrkA kinase inhibitor CT327 is an effective, novel therapy for the treatment of pruritus due to psoriasis: results from experimental studies, and efficacy and safety of CT327 in a phase 2b clinical trial in patients with psoriasis. Acta Derm Venereol. 2015;95(5):542–548.
   PubMed Web of Science ®Google Scholar
• Traversa S, Bagnod R, Barone D, et al. Polymer conjugates of k-252a and derivatives thereof. WO2007022999 A1. 2007
   Google Scholar
• Song Y, Bridges AJ Macrocyclic compounds for the treatment of proliferative diseases. WO2015050989 A2. 2015
   Google Scholar
• Bailey S, Burke BJ, Collins MR, et al. Macrocyclic derivatives for the treatment of proliferative diseases. WO2013132376 A1. 2013
   Google Scholar
• Jensen AJ, Luthra S, Richardson PF Solid forms of a macrocyclic kinase inhibitor. WO2014207606 A1. 2014
   Google Scholar
• Takeda Y, Yoshikawa K, Kagoshima Y, et al. Imidazo[1,2-b]pyridazine derivative as kinase inhibitor. WO2013183578. 2013
   Google Scholar
• Flynn DL, Kaufman MD, Smith BD Inhibition of trk kinase mediated tumor growth and disease progression. WO2016061228 A1. 2016
   Google Scholar
• Flynn DL, Kaufman MD Cyclopropyl dicarboxamides and analogs exhibiting anti-cancer and anti-proliferative activites. WO2011137342 A1. 2011
   Google Scholar
• Bannen LC, Chan DSM, Chen J, et al. C-met modulators and methods of use. WO2005030140 A2. 2005
   Google Scholar
• Smith BD, Kaufman MD, Leary CB, et al. Altiratinib inhibits tumor growth, invasion, angiogenesis, and microenvironment-mediated drug resistance via balanced inhibition of MET, TIE2, and VEGFR2. Mol Cancer Ther. 2015;14(9):2023–2034.
   PubMed Web of Science ®Google Scholar
• Piao Y, Park SY, Henry V, et al. Novel MET/TIE2/VEGFR2 inhibitor altiratinib inhibits tumor growth and invasiveness in bevacizumab-resistant glioblastoma mouse models. Neuro Oncol. 2016;18(9):1230–1241.
   PubMed Web of Science ®Google Scholar
• Shewchuk L, Hassell A, Holmes W, et al. Crystal structure of liganded cFMS kinase domain. US20040002145 A1. 2004
   Google Scholar
• Kane JL, Matthews G, Metz M, et al. Tropomyosin-related kinase (trk) inhibitors. WO2015089139 A1. 2015
   Google Scholar
• Lieberman H, Yang D, Philbrook CM, et al. Pharmaceutical formulations of tropomyosin related kinase (trk) inhibitors. WO2016100677 A2. 2016
   Google Scholar
• Blasioli D, Donahue K, Flannery C, et al. Cyclic urea compounds as tropomyosin-related kinase (trk) inhibitors. WO2016036796 A1. 2016
   Google Scholar
• Albaugh PA, Chopiuk G, Fan Y, et al. Imidazo [1, 2] pyridazin compounds and compositions as trk inhibitors. WO2012034091 A1. 2012
   Google Scholar
• Molteni V, Fan Y, Loren J, et al. Compounds and compositions as trk inhibitors. WO2012116217 A1. 2012
   Google Scholar
• Albaugh PA, Chopiuk G, Fan Y, et al. Compounds and compositions as trk inhibitors. WO2012034095 A1. 2012
   Google Scholar
• Chakravarty S, Rai R, Green MJ, et al. Fused pyrimidine compounds and use thereof. WO2014105958 A2. 2014
   Google Scholar
• George DJ, Dionne CA, Jani J, et al. Sustained in vivo regression of dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555). Cancer Res. 1999;59(10):2395–2401.
   PubMed Web of Science ®Google Scholar
• Shabbir M, Stuart R. Lestaurtinib, a multitargeted tyrosinse kinase inhibitor: from bench to bedside. Expert Opinion on Investigational Drugs. 2010;19(3):427–436.
   PubMed Web of Science ®Google Scholar
• Minturn JE, Evans AE, Villablanca JG, et al. Phase I trial of lestaurtinib for children with refractory neuroblastoma: a new approaches to neuroblastoma therapy consortium study. Cancer Chemother Pharmacol. 2011;68(4):1057–1065.
   PubMed Web of Science ®Google Scholar
• Reddy AS, Zhang S. Polypharmacology: drug discovery for the future. Expert Rev Clin Pharmacol. 2013;6(1):41–47.
   PubMed Web of Science ®Google Scholar
• Albanese C, Alzani R, Amboldi N, et al. Anti-tumour efficacy on glioma models of PHA-848125, a multi-kinase inhibitor able to cross the blood–brain barrier. Br J Pharmacol. 2013;169(1):156–166.
   PubMed Web of Science ®Google Scholar